Alembic Pharmaceuticals Limited has scheduled one-to-one meetings with investors and analysts on September 1 and 2, 2026. The company confirmed that no unpublished price-sensitive information will be disclosed during these sessions.

The management team will engage with several institutional investors and brokerages across two days. The schedule includes both in-person interactions in Mumbai and virtual sessions via video conferencing.

Meeting Schedule

The engagements are distributed as follows:

Chirag K. Shukla, Company Secretary, signed the intimation letter dated August 27, 2026. The company notified the Bombay Stock Exchange and the National Stock Exchange of India Ltd regarding these scheduled discussions.

Alembic Pharmaceuticals has appointed Chirag Shukla as Company Secretary and Compliance Officer effective August 20, 2026. The firm disclosed the change in management to stock exchanges on the same date.

Shukla joins as a Key Managerial Personnel with permanent employment status. The appointment follows the company's compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. G Krishnan, Chief Financial Officer, signed the intimation letter submitted to the BSE and NSE.

Profile and Experience

Shukla is a qualified Company Secretary and Law Graduate with over 19 years of experience in corporate secretarial, legal, and compliance functions. His professional background includes roles at Deepak Phenolics Limited, a subsidiary of Deepak Nitrite Limited.

He has previously worked with Schaeffler India Limited, Alembic Limited, and Bhavnagar Energy Company Limited. His expertise covers compliance under the Companies Act, 2013, SEBI Regulations, corporate governance matters, and corporate restructuring.

Regulatory Disclosure

The company filed the details under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing confirmed no relationships between directors regarding this appointment.